Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status

By afschroeder • October 25, 2025

Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov;26(7):e503-e513.e11. doi: 10.1016/j.cllc.2025.05.016. Epub 2025 Jun 6. PMID: 40582920.

Tags: ALK inhibitors, Cedars Sinai DoM, circulating tumor DNA, G1202R, Hematology/Oncology, Publications, Resistance mutations, Tumor biopsy

Specific targeting of cancer cell mitochondria with a malaria drug improves pancreatic cancer outcome

Ou Y, Lim A, Wang R, Mir N, Calsavara VF, Wang Q, Zhang Y, Pandol SJ, Edderkaoui M. Specific targeting of cancer cell mitochondria with[...]

Beyond the field of view: Radiomics and artificial intelligence for organ-specific and systemic disease prediction from localized medical imaging

Wang L, Shi Y, Deng Z, Wang Y, Rigo De Righi D, Javed S, Qureshi TA, Yang JD, Xie Y, Pandol SJ, Li D. Beyond[...]

Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort

Vershel C, Kim S, Gensler LS, Brown MA, Weisman MH, Ishimori ML, Ward M, Reveille JD, Hwang MC. Examining the Interchangeability of Two Different Patient-Reported[...]